153 related articles for article (PubMed ID: 23998557)
1. A study on the efficacy and safety assessment of propionyl-L-carnitine tablets in treatment of intermittent claudication.
Luo T; Li J; Li L; Yang B; Liu C; Zheng Q; Jin B; Chen Z; Li K; Zhang X; Zhang J
Thromb Res; 2013 Oct; 132(4):427-32. PubMed ID: 23998557
[TBL] [Abstract][Full Text] [Related]
2. Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study.
Brevetti G; Perna S; Sabbá C; Martone VD; Condorelli M
J Am Coll Cardiol; 1995 Nov; 26(6):1411-6. PubMed ID: 7594063
[TBL] [Abstract][Full Text] [Related]
3. Propionyl-L-carnitine for intermittent claudication.
Kamoen V; Vander Stichele R; Campens L; De Bacquer D; Van Bortel L; de Backer TL
Cochrane Database Syst Rev; 2021 Dec; 12(12):CD010117. PubMed ID: 34954832
[TBL] [Abstract][Full Text] [Related]
4. L-Carnitine plus cilostazol versus cilostazol alone for the treatment of claudication in patients with peripheral artery disease: a multicenter, randomized, double-blind, placebo-controlled trial.
Goldenberg NA; Krantz MJ; Hiatt WR
Vasc Med; 2012 Jun; 17(3):145-54. PubMed ID: 22615190
[TBL] [Abstract][Full Text] [Related]
5. Effect of propionyl-L-carnitine on a background of monitored exercise in patients with claudication secondary to peripheral artery disease.
Hiatt WR; Creager MA; Amato A; Brass EP
J Cardiopulm Rehabil Prev; 2011; 31(2):125-32. PubMed ID: 20861750
[TBL] [Abstract][Full Text] [Related]
6. Randomised clinical trial: the efficacy and safety of propionyl-L-carnitine therapy in patients with ulcerative colitis receiving stable oral treatment.
Mikhailova TL; Sishkova E; Poniewierka E; Zhidkov KP; Bakulin IG; Kupcinskas L; Lesniakowski K; Grinevich VB; Malecka-Panas E; Ardizzone S; D'Arienzo A; Valpiani D; Koch M; Denapiene G; Vago G; Fociani P; Zerbi P; Ceracchi M; Camerini R; Gasbarrini G
Aliment Pharmacol Ther; 2011 Nov; 34(9):1088-97. PubMed ID: 21929562
[TBL] [Abstract][Full Text] [Related]
7. A systematic review to evaluate the effectiveness of carnitine supplementation in improving walking performance among individuals with intermittent claudication.
Delaney CL; Spark JI; Thomas J; Wong YT; Chan LT; Miller MD
Atherosclerosis; 2013 Jul; 229(1):1-9. PubMed ID: 23557982
[TBL] [Abstract][Full Text] [Related]
8. Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication.
Hiatt WR; Regensteiner JG; Creager MA; Hirsch AT; Cooke JP; Olin JW; Gorbunov GN; Isner J; Lukjanov YV; Tsitsiashvili MS; Zabelskaya TF; Amato A
Am J Med; 2001 Jun; 110(8):616-22. PubMed ID: 11382369
[TBL] [Abstract][Full Text] [Related]
9. Propionyl-L-Carnitine versus Pentoxifylline : Improvement in Walking Capacity in Patients with Intermittent Claudication.
Strano A
Clin Drug Investig; 2002 Nov; 22(Suppl 1):1-6. PubMed ID: 23315429
[TBL] [Abstract][Full Text] [Related]
10. Results from a phase II multicenter, double-blind placebo-controlled study of Del-1 (VLTS-589) for intermittent claudication in subjects with peripheral arterial disease.
Grossman PM; Mendelsohn F; Henry TD; Hermiller JB; Litt M; Saucedo JF; Weiss RJ; Kandzari DE; Kleiman N; Anderson RD; Gottlieb D; Karlsberg R; Snell J; Rocha-Singh K
Am Heart J; 2007 May; 153(5):874-80. PubMed ID: 17452167
[TBL] [Abstract][Full Text] [Related]
11. Effect of niacin ER/lovastatin on claudication symptoms in patients with peripheral artery disease.
Hiatt WR; Hirsch AT; Creager MA; Rajagopalan S; Mohler ER; Ballantyne CM; Regensteiner JG; Treat-Jacobson D; Dale RA; Rooke T
Vasc Med; 2010 Jun; 15(3):171-9. PubMed ID: 20212073
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the efficacy of propionyl-L-carnitine versus pulsed muscular compressions in diabetic and non-diabetic patients affected by obliterating arteriopathy Leriche stage II.
Riccioni C; Sarcinella R; Palermo G; Izzo A; Liguori M; Koverech A; Messano M; Virmani A
Int Angiol; 2008 Jun; 27(3):253-9. PubMed ID: 18506129
[TBL] [Abstract][Full Text] [Related]
13. Effect of nebivolol vs. hydrochlorothiazide on the walking capacity in hypertensive patients with intermittent claudication.
Diehm C; Pittrow D; Lawall H
J Hypertens; 2011 Jul; 29(7):1448-56. PubMed ID: 21602713
[TBL] [Abstract][Full Text] [Related]
14. European multicenter study on propionyl-L-carnitine in intermittent claudication.
Brevetti G; Diehm C; Lambert D
J Am Coll Cardiol; 1999 Nov; 34(5):1618-24. PubMed ID: 10551714
[TBL] [Abstract][Full Text] [Related]
15. A randomized trial of iloprost in patients with intermittent claudication.
Creager MA; Pande RL; Hiatt WR
Vasc Med; 2008 Feb; 13(1):5-13. PubMed ID: 18372433
[TBL] [Abstract][Full Text] [Related]
16. Treatment of intermittent claudication with pentoxifylline: a 12-month, randomized trial--walking distance and microcirculation.
De Sanctis MT; Cesarone MR; Belcaro G; Nicolaides AN; Griffin M; Incandela L; Bucci M; Geroulakos G; Ramaswami G; Vasdekis S; Agus G; Bavera P; Ippolito E
Angiology; 2002; 53 Suppl 1():S7-12. PubMed ID: 11865838
[TBL] [Abstract][Full Text] [Related]
17. Improving walking ability and ankle brachial pressure indices in symptomatic peripheral vascular disease with intermittent pneumatic foot compression: a prospective controlled study with one-year follow-up.
Delis KT; Nicolaides AN; Wolfe JH; Stansby G
J Vasc Surg; 2000 Apr; 31(4):650-61. PubMed ID: 10753272
[TBL] [Abstract][Full Text] [Related]
18. A systematic review and meta-analysis of propionyl-L-carnitine effects on exercise performance in patients with claudication.
Brass EP; Koster D; Hiatt WR; Amato A
Vasc Med; 2013 Feb; 18(1):3-12. PubMed ID: 23321261
[TBL] [Abstract][Full Text] [Related]
19. Anti-chlamydial antibiotic therapy for symptom improvement in peripheral artery disease: prospective evaluation of rifalazil effect on vascular symptoms of intermittent claudication and other endpoints in Chlamydia pneumoniae seropositive patients (PROVIDENCE-1).
Jaff MR; Dale RA; Creager MA; Lipicky RJ; Constant J; Campbell LA; Hiatt WR
Circulation; 2009 Jan; 119(3):452-8. PubMed ID: 19139383
[TBL] [Abstract][Full Text] [Related]
20. A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication.
Brass EP; Cooper LT; Morgan RE; Hiatt WR
J Vasc Surg; 2012 Feb; 55(2):381-389.e1. PubMed ID: 22119244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
